Clinical Trial Update: Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on safety, tolerability, and immunogenicity of Gam-COVID-Vac delivered as a nasal spray.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2 Acute Respiratory Disease

Drugs mentioned

• Gam-COVID-Vac (unspecified)

Snippet

Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Conditions: COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 1, Phase 2 | Status: UNKNOWN